1FW2:F:F-WUXI BIOLOGICS-00000083 (EUR)

COMMON STOCK | Biotechnology |

Last Closing

USD 1.3466

Change

0.00 (0.00)%

Market Cap

USD 5.61B

Volume

599.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-03 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NOV:F Novo Nordisk A/S

N/A

USD 526.04B
NOVA:F Novo Nordisk A/S

N/A

USD 524.27B
RGO:F Regeneron Pharmaceuticals Inc

N/A

USD 117.89B
CSJA:F CSL LTD SPON.ADR 2

N/A

USD 91.04B
CSJ:F CSL Limited

N/A

USD 91.04B
UNC0:F UCB S.A. UNSP.ADR 1/2

N/A

USD 31.06B
DUL:F Alnylam Pharmaceuticals Inc

N/A

USD 30.44B
1AE:F Argen-X

N/A

USD 29.24B
1AEA:F argenx SE

N/A

USD 29.18B
0QF:F Moderna Inc

N/A

USD 25.22B

ETFs Containing 1FW2:F

FID First Trust Intl Multi-As.. 1.91 % 0.69 %

N/A

USD 0.08B
DVYA iShares Asia/Pacific Divi.. 0.00 % 0.49 %

N/A

N/A
EWH iShares MSCI Hong Kong ET.. 0.00 % 0.48 %

N/A

N/A
FGD First Trust Dow Jones Glo.. 0.00 % 0.58 %

N/A

N/A
IFGL iShares International Dev.. 0.00 % 0.48 %

N/A

USD 0.10B
SCZ iShares MSCI EAFE Small-C.. 0.00 % 0.39 %

N/A

USD 9.12B
3110:HK Global X Hang Seng High D.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -59.87% 12% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -59.87% 12% F 5% F
Trailing 12 Months  
Capital Gain -74.08% 11% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -74.08% 11% F 5% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -24.78% 16% F 6% D-
Dividend Return -24.78% 16% F 6% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 33.50% 49% F 36% F
Risk Adjusted Return -73.96% 10% F 5% F
Market Capitalization 5.61B 94% A 80% B-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.